InnoCare Pharma Ltd, a Hong Kong-listed Chinese mainland biotech company, said on Thursday that its cancer drug ...
ADVERTISEMENT ADVERTISEMENT Breaking News Intern Jason Collins, the first active NBA player to come out as gay, has terminal ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK ...
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing ...
Glioblastoma is the most common form of brain cancer in adults, and its consequences are usually quick and fatal. After ...
Protesters interrupted Homeland Security Secretary Kristi Noem’s Capitol Hill hearing on Thursday, with one shouting a line ...
Preoperative breast MRI did not improve LRR, DRFR, or OS outcomes in early-stage breast cancer patients. The trial involved ...
Ten percent higher 5-year overall survival rates in patients receiving precise proton therapy vs. traditional radiation therapyPatients had significantly ...
Pfizer announces Tukysa added to first-line maintenance therapy extends median PFS by over 8 months in patients with HER2+ metastatic breast cancer: New York Friday, December 12, ...
Kinsella's novels have sold over 45 million copies in more than 60 countries and have been translated into over 40 languages ...
InnoCare Pharma (INCPF) received approval from the China National Medical Products Administration for the treatment of adult and adolescent patients with solid tumors harboring NTRK gene fusions. In ...
Tucatinib addition to trastuzumab and pertuzumab significantly improved PFS in HER2-positive metastatic breast cancer, with a median PFS of 24.9 months versus 16.3 months with placebo. The PFS benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback